{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"Hyperphosphataemia (serum phosphorus \\> 1.78 mmol/L), based on laboratory data, was collected during the observed 6 months treatment with Zemplar (paricalcitol injection).","groups":[{"description":"Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)","id":"OG000","title":"End-stage Kidney Disease With Secondary Hyperparathyroidism"}],"paramType":"NUMBER","populationDescription":"Participants with available retrospective data (cohort analyzed for Outcome Measure 8) were analyzed prospectively at Month 6 of treatment.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Number of Participants With Hyperphosphataemia During 6 Months of Selective Vitamin D Receptor Activator (Paricalcitol) Treatment","type":"SECONDARY","unitOfMeasure":"participants"}